Keywords
MedicineTrastuzumabMonoclonal antibodyMonoclonalOncologyBreast cancerAntibodyHumanized antibodyCancerCancer researchImmunologyInternal medicine
Related Publications
Trastuzumab-Induced Hepatotoxicity: A Case Report
<b><i>Background: </i></b>Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overe...
Detection of Surface Antigen 17-1A in Breast and Colorectal Cancer
Substantial progress has been made in detecting cell surface or intracytoplasmatic antigens to identify spread tumor cells with monoclonal antibodies (MAbs). The 17-1A antigen i...
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation.
The cell surface-binding properties of two murine monoclonal antibodies reactive with human mammary tumor cells are described. Fluorescence-activated cell sorter analyses demons...
Monoclonal autoantibodies to subnucleosomes from a MRL/Mp(-)+/+ mouse. Oligoclonality of the antibody response and recognition of a determinant composed of histones H2A, H2B, and DNA.
Abstract MRL/Mp(-)+/+ mice produce antinuclear antibodies and develop a spontaneous autoimmune syndrome with lupus-like nephritis. We obtained a panel of seven histone-reactive ...
Interleukin-6 Receptor Blockade Selectively Reduces IL-21 Production by CD4 T Cells and IgG4 Autoantibodies in Rheumatoid Arthritis
Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces diseas...
Publication Info
- Year
- 1999
- Type
- article
- Volume
- 35
- Issue
- 12
- Pages
- 931-931
- Citations
- 113
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
113
OpenAlex
Cite This
Joan Albanell,
José Baselga
(1999).
Trastuzumab, a humanized anti-HER2 monoclonal antibody, for thetreatment of breast cancer.
Drugs of today
, 35
(12)
, 931-931.
https://doi.org/10.1358/dot.1999.35.12.564040
Identifiers
- DOI
- 10.1358/dot.1999.35.12.564040